Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina

Página de ítem simple
cic.isFulltextSI
cic.isPeerReviewedtrue
cic.lugarDesarrolloMinisterio de Salud
cic.lugarDesarrolloUniversidad Nacional de La Plata
cic.lugarDesarrolloUniversidad de Buenos Aires
cic.lugarDesarrolloHospital Interzonal de Agudos Especializado en Pediatría "Sor María Ludovica"
cic.parentTypeArtículo
cic.versionPublicada
dc.date.accessioned2023-03-28T14:00:01Z
dc.date.available2023-03-28T14:00:01Z
dc.identifier.urihttps://digital.cic.gba.gob.ar/handle/11746/11784
dc.titleEffectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentinaen
dc.typeArtículo
dcterms.abstractBackground A first-dose of various vaccines provides acceptable protection against infections by SARS-CoV-2 and evolution to the most severe forms of COVID-19. The recombinant adenovirus (rAd)-based vaccine, Gam-COVID-Vac (Sputnik V), was proven efficacious but information about effectiveness in the real-world setting is lacking. The aim of our study was to investigate the association between the rollout of the first component (rAd26) of Gam-COVID-Vac and PCR-positive tests, hospitalisations and deaths. Methods We conducted a retrospective cohort study which analyzed individuals aged 60-79 who self-registered in the online vaccination system of the Province of Buenos Aires, Argentina, from December 29, 2020 to March 21, 2021. Exclusion criteria were having a previous positive RT-PCR or antigen tests for SARS-CoV-2, having received other vaccines, or two doses of any vaccine. Proportions of new laboratory-confirmed SARS-CoV-2 infections, hospitalisations and deaths until 83 days of vaccination were compared between vaccinated and unvaccinated subjects. Vaccine effectiveness for the three outcomes was calculated as (1–OR) × 100. Kaplan-Meier cumulative incidence curves were constructed. Findings During the study period 415995 registered subjects received the first component of Gam-COVID-Vac; 40387 belonged to the 60-79 age group, and were compared to 38978 unvaccinated. Vaccine effectiveness for preventing laboratory-confirmed infections was 78•6% [CI95% 74·8 - 81·7]; and for reducing hospitalizations and deaths was, respectively, 87·6% [CI95% 80·3 - 92·2] and 84·8% [CI95% 75·0 - 90·7]. Effectiveness was high across all subgroups. Interpretation Similarly to other vaccines, the administration of one dose of Gam-COVID-Vac was effective for a wide range of COVID-19–related outcomes.en
dcterms.creator.authorGonzález, Soledad E.
dcterms.creator.authorOlszevicki, Santiago
dcterms.creator.authorSalazar, Martín R.
dcterms.creator.authorCalabria, Ana
dcterms.creator.authorRegairaz, Lorena
dcterms.creator.authorMarín, Lupe
dcterms.creator.authorCampos, Patricia
dcterms.creator.authorVarela, Teresa
dcterms.creator.authorGonzález Martínez, Veronica V.
dcterms.creator.authorCeriani, Leticia
dcterms.creator.authorGarcia, Enio
dcterms.creator.authorKreplak, Nicolás
dcterms.creator.authorPifano, Marina
dcterms.creator.authorEstenssoro, Elisa
dcterms.creator.authorMarsico, Franco
dcterms.identifier.otherISSN: 2589-5370
dcterms.identifier.otherDOI: 10.1016/j.eclinm.2021.101126
dcterms.isPartOf.issuevol. 40
dcterms.isPartOf.seriesEClinicalMedicine
dcterms.issued2021
dcterms.languageInglés
dcterms.licenseAttribution-NonCommercial-NoDerivatives 4.0 International (BY-NC-ND 4.0)
dcterms.subjectVaccinationen
dcterms.subjectcovid-19en
dcterms.subjectImmunizationen
dcterms.subjectCnfectious diseasesen
dcterms.subject.materiaCiencias Médicas y de la Salud

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
Effectiveness of the first component of Gam-COVID-Vac.pdf
Tamaño:
1.06 MB
Formato:
Adobe Portable Document Format
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
3.46 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos, Informes y presentaciones en Congresos